AbbVie on Wednesday said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion. Under the terms of the deal, AbbVie will pay $45 per share for Cerevel. AbbVie said it… [+1455 chars]Read More
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for 87 billion CNBC
